Eufe 1979.

Methods	Allocation: randomised (implied). Blindness: double. Duration: 12 weeks.
Participants	Diagnosis: schizophrenia (ICD 9). History: all participants were chronically ill, mean duration of illness ‐ perphenazine 19.5 years, flupenthixol 20.3 years. N = 32. Age: mean age for perphenazine group 45.3 years, flupenthixol group 48.8 years. Sex: 28 men, 4 women. Setting: community/hospitalised.
Interventions	1. Flupenthixol decanoate: 20 mg/ml biweekly. 2. Perphenazine enanthate: 100 mg/ml biweekly.
Outcomes	Global state ‐ 'not clearly better', and 'not minimally better' (five‐point scale). Adverse effects ‐ requiring anticholinergic medication. Leaving study early due to any reason. Unable to use ‐ Mental state (BPRS ‐ no SD). Side effects (AMP ‐ no data). NOSIE (no 12 week data).
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	'Allocated according to chance'. No other information.
Allocation concealment (selection bias)	Unclear risk	Method of allocation concealment not described.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Says it is double blind. 'Same injection interval and dose kept constant', no other information.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Intention‐to‐treat analyses done, LOCF, only 3 patients dropped out.
Selective reporting (reporting bias)	Unclear risk	Some outcomes of interest regarding Mental State, side effects and nurses assessments were reported incompletely so cannot be entered in meta‐analysis.
Other bias	Low risk	No obvious other bias.